tbuckley/cabot-search huggingface dataset:
Lead Exposure as a Confounding Factor in the Association of Air Pollution Exposure and Psychotic Experiences
Authors: Esme Fuller-Thomson, Amy P. Munro
Journal: JAMA Psychiatry (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
TNF-α–driven inflammation and mitochondrial dysfunction define the platelet hyperreactivity of aging
Authors: Pavel Davizon-Castillo, Brandon McMahon, Sonia Aguila, David Bark, Katrina Ashworth, Ayed Allawzi, Robert A. Campbell, Emilie Montenont, Travis Nemkov, Angelo D’Alessandro, Nathan Clendenen, Lauren Shih, Natalie A. Sanders, Kelly Higa, Allaura Cox, Zavelia Padilla-Romo, Giovanni Hernandez, Eric Wartchow, George D. Trahan, Eva Nozik-Grayck, Kenneth Jones, Eric M. Pietras, James DeGregori, Matthew T. Rondina, Jorge Di Paola
Journal: Blood (2019)
Targeted tumor-derived cellular immunotherapy in advanced breast cancer patients induces initial immune responses and tumor regression.
Authors: Vivekananda Sunkari, William Williams, George Peoples, Sanne Graeve, Charles Wiseman, Markus Lacher
Journal: Journal of Clinical Oncology (2019)

6 Background: SV-BR-1-GM is a GM-CSF secreting breast cancer cell line which also expresses HLA class I &amp; II antigens. In a previous clinical trial, a partial response of widely metastatic breast cancer was seen in a patient who allele-matched SV-BR-1-GM at HLA-DRB3. Here we report regression of metastatic breast cancer and efficacy analysis with immunologic correlates in subjects of a Phase I/IIa trial of SV-BR-1-GM in patients with advanced breast cancer. Methods: 24 patients with recurrent and/or metastatic breast cancer refractory to standard therapies have been dosed with SV-BR-1-GM in a Phase I/IIa trial. Patients who have undergone at least one cycle of SV-BR-1-GM therapy were analyzed. Patients first received low-dose cyclophosphamide, then intradermal injection of SV-BR-1-GM (20-40x10 6 cells/four sites) with interferon-α injected into inoculation sites (10,000 IU/site) ~2 &amp; 4 days subsequently. Immunologic responses were measured by delayed type hypersensitivity (DTH) after inoculation and IgG titers of antibodies against SV-BR-1 were measured in sera samples collected prior to and after the first dose of SV-BR-1-GM by flow cytometry. Results: 24 patients have been inoculated with SV-BR-1-GM cells with no unexpected adverse events. None of the patients exhibited immediate hypersensitivity to SV-BR-1. DTH response was recorded in 18 subjects till date, of these, 61% exhibited DTH to cell inoculations. The patient with the most marked DTH response, 01-002, also had a clinical response with regression of multiple lung metastases. Two other patients had evidence of tumor regression (tumor regression is matched SV-BR-1-GM at least at one HLA allele). Sera samples from 6 patients were evaluated and found to contain anti-SV-BR-1 antibodies. Conclusions: SV-BR-1-GM in this regimen appears to be safe and well-tolerated. Initial analysis of SV-BR-1-GM showed significant DTH and antibody responses. HLA matching improves the response rate and is being evaluated as a predictor of response. Clinical trial information: NCT03066947.
Patient satisfaction with GPs remains high despite current pressures
Authors: Susan Mayor
Journal: BMJ (2019)

More than eight in 10 patients considered their overall experience of their GP practice was good, results from the latest GP Patient Survey for nearly 800 000 patients across England showed.1

The annual survey asks patients about their experience of healthcare services provided by GP practices, including the quality of care received from healthcare professionals, access, and making appointments.

The 2019 survey included aggregated data from 770 512 patients responding to postal questionnaires sent to 2.3 million adults registered with GP practices in England from January 2019 to the end of March 2019 (33.1% response rate).

Results showed that 82.9% of respondents rated their overall experience of their GP …
Circulating tumor cells in advanced non-small cell lung cancer patients are associated with worse tumor response to checkpoint inhibitors
Authors: Menno Tamminga, Sanne de Wit, T. Jeroen N. Hiltermann, Wim Timens, Ed Schuuring, Leon W. M. M. Terstappen, Harry J. M. Groen
Journal: Journal for ImmunoTherapy of Cancer (2019)

Non-small cell lung cancer (NSCLC) patients treated with checkpoint inhibitors show long lasting responses, but it is hard to predict which patients will profit from this treatment with the currently used marker, programmed death ligand 1 (PD-L1). We hypothesized that circulating tumor cells (CTC) or tumor derived extracellular vesicles (tdEV) are markers of treatment efficacy.Patients with advanced NSCLC treated with checkpoint inhibitors were included. Blood was drawn at baseline (T0) and at 4 weeks of treatment (T1) for analysis of CTC and tdEV using CellSearch®. Tumor response was classified as partial or complete response based on the response evaluation criteria in solid tumors (RECISTv1.1) measured 4-6 weeks after start of treatment. Durable response was defined as stable disease, partial or complete response without disease progression at 6 months. Analyses were adjusted for covariables including PD-L1 expression.We included 104 patients (30 with a tumor response, 74 non-responders, 2 responses not evaluable due to early death); 63 patients provided T1 samples. All patients were treated with PD-L1 inhibitors. The majority of patients received second (85%) or third line (treatment with nivolumab monotherapy (89%). CTC were present in 33/104 patients at T0 (32%) and 17/63 at T1 (27%), 9/63 patients had CTC (14%) at both time points. The presence of CTC, both at T0 (OR = 0.28, p = 0.02,) and T1 (OR = 0.07, p < 0.01), was an independent predictive factor for a lack of durable response and was associated with worse progression free and overall survival. More tdEV were associated with shorter survival but not with response rate.CTC occur in one third of advanced NSCLC patients and their presence is a predictive factor for a worse durable response rate to checkpoint inhibitors. tdEV are associated with shorter survival but not with response.
Lifetime Economic Burden of Crohn’s Disease and Ulcerative Colitis by Age at Diagnosis
Authors: Gary R. Lichtenstein, Ahva Shahabi, Seth A. Seabury, Darius N. Lakdawalla, Oliver Díaz Espinosa, Sarah Green, Michelle Brauer, Robert N. Baldassano
Journal: Clinical Gastroenterology and Hepatology (2019)
A middle aged man with back pain and heavy legs
Authors: Neil Chanchlani, Nick G Reading
Journal: BMJ (2019)

A 50 year old man presented with a two day history of “heavy legs,” reduced sensation bilaterally in his lower limbs, and five days of constipation. He had also experienced right upper quadrant pain for one month, and had a history of mechanical lumbar back pain for the preceding six weeks 

His abdomen was mildly distended and diffusely tender. Rectal examination revealed packed faeces. He was able to walk, but dragged his legs and had bilateral global lower limb muscle wasting. Power grade in both lower limbs was 4/5 (proximally and distally) and he had bilateral hyperreflexia. He had reduced sensation in both lower limbs at L4, L5, and …
Phase I study to evaluate the safety and efficacy of rivoceranib (apatinib) and nivolumab in patients with unresectable or metastatic cancer.
Authors: Sant P. Chawla, Victoria S. Chua, Erlinda Maria Gordon, Ania Moradkhani, Katherine Kim, Doris Quon, Steven Wong, Robert Sumner, Virginia Mac, Raymond Huang, Kelly Wang, Jiyeun Kim, Bumjin Kim, Arlo N. McGinn, Cheol Hee Park, Scott Houston, Neil Sankar
Journal: Journal of Clinical Oncology (2019)

18 Background: Due to their immuno-modulatory effects, anti-angiogenic drugs have been clinically investigated in combination with anti-PD-1 therapies. The addition of rivoceranib (apatinib), a highly-selective VEGFR-2 tyrosine kinase inhibitor, is being evaluated in an ongoing 2-part Phase I trial in subjects with locally advanced unresectable/metastatic solid tumors who have received at least 3 doses of nivolumab. A classic 3+3 dose escalation has been completed (Part 1) and the study is currently ongoing with an extension period (Part 2). Herein, we present the safety and preliminary efficacy. Methods: To date, 10 subjects were enrolled in Part 1 while 3 subjects have been enrolled in Part 2. Median number of prior lines of therapy were 3 and 1, respectively, for the two study segments. The major inclusion criteria specified that patients must have received at least 3 doses of nivolumab and are continuing nivolumab therapy. Escalating doses of rivoceranib at 400, 600, and 700 mg po qd was proposed in combination with nivolumab at 240 mg iv q2w to determine the MTD. Best tumor response and time of progression was assessed using RECIST v1.1 and iRECIST. Results: 300 mg rivoceranib was determined as RP2D for Part 2. 5/13 patients had G2/3 hypertension. Common treatment-related AEs were hypertension, hand and foot syndrome, and nausea and immune-related AEs were hypothyroidism and diarrhea. Notably, in 10 evaluable patients, 3 patients had PD and 4 patients showed tumor shrinkage (5-29%). A patient with Malignant Spindled/Epitheloid Sarcoma, who had PD during previous nivolumab treatment has shown tumor reduction, so far, of 9%. A patient with Gastric Cancer, who had stable disease (a 4% increase) after 2 months of nivolumab showed a reduction of 29%, 2 months after introduction of rivoceranib. 2 patients have had stable disease for more than 8 months as of Oct 26, 2018. Conclusions: Preliminary results indicate the potential clinical benefit of a 300 mg starting dose in combination with 240 mg of nivolumab in unresectable/metastatic solid tumors with a tolerable safety profile. Efficacy of ongoing and future patients in Part 2 will be further evaluated. Clinical trial information: NCT03396211.
Abstract 689: Serial Changes in Von Willebrand Factor-cleaving Protease (ADAMTS13) and Prognosis after Acute Myocardial Infarction
Authors: masakazu matsukawa, Koichi Kaikita, Kenji Soejima, Shunichirou Fuchigami, Tsuyoshi Honda, Yoshinori Nakamura, Takashi Kudo, Kenichi Tsujita, Sunao Kojima, Hideki Shimomura, Seigo Sugiyama, Kazuteru Fujimoto, Michihiro Yoshimura, Hisao Ogawa
Journal: Circulation (2006)

Von WilIebrand factor (VWF) enhances haemostasis and thrombosis as an important cofactor in platelet adhesion and aggregation. Recently, a metalloprotease that cleaves VWF multimers has been identi...
Matrix stiffness induces a tumorigenic phenotype in mammary epithelium through changes in chromatin accessibility
Authors: Ryan S. Stowers, Anna Shcherbina, Johnny Israeli, Joshua J. Gruber, Julie Chang, Sungmin Nam, Atefeh Rabiee, Mary N. Teruel, Michael P. Snyder, Anshul Kundaje, Ovijit Chaudhuri
Journal: Nature Biomedical Engineering (2019)
One‐Pot Synthesis of Unsaturated Polyester Bioelastomer with Controllable Material Curing for Microscale Designs
Authors: Locke Davenport Huyer, A. Dawn Bannerman, Yufeng Wang, Houman Savoji, Ericka J. Knee‐Walden, Amanda Brissenden, Bess Yee, Mohammad Shoaib, Erin Bobicki, Brian G. Amsden, Milica Radisic
Journal: Advanced Healthcare Materials (2019)

Abstract Synthetic polyester elastomeric constructs have become increasingly important for a range of healthcare applications, due to tunable soft elastic properties that mimic those of human tissues. A number of these constructs require intricate mechanical design to achieve a tunable material with controllable curing. Here, the synthesis and characterization of poly(itaconate‐ co‐ citrate‐ co‐ octanediol) (PICO) is presented, which exhibits tunable formation of elastomeric networks through radical crosslinking of itaconate in the polymer backbone of viscous polyester gels. Through variation of reaction times and monomer molar composition, materials with modulation of a wide range of elasticity (36–1476 kPa) are generated, indicating the tunability of materials to specific elastomeric constructs. This correlated with measured rapid and controllable gelation times. As a proof of principle, scaffold support for cardiac tissue patches is developed, which presents visible tissue organization and viability with appropriate elastomeric support from PICO materials. These formulations present potential application in a range of healthcare applications with requirement for elastomeric support with controllable, rapid gelation under mild conditions.
A phase 1b study of IMU-131 her2/neu peptide vaccine plus chemotherapy in patients with HER2/neu overexpressing metastatic or advanced adenocarcinoma of the stomach or gastroesophageal junction
Authors: M. Maglakelidze, T. Yau, I. Bulat, C. Yen, Y. Chao, L. Bai, A. Good, N. Ede, L. Chong, S. Tanasanvimon, C. Charoetum, H. Loong, W. Lausoontornsiri, W. Arpornwirat, J. Maneechavakajon, T. Ungtrakul, W. Chou
Journal: Annals of Oncology (2019)
Hydrogen Therapy: Acid‐Responsive H<sub>2</sub>‐Releasing 2D MgB<sub>2</sub> Nanosheet for Therapeutic Synergy and Side Effect Attenuation of Gastric Cancer Chemotherapy (Adv. Healthcare Mater. 13/2019)
Authors: Mingjian Fan, Yanyuan Wen, Dien Ye, Zhaokui Jin, Penghe Zhao, Danyang Chen, Xifeng Lu, Qianjun He
Journal: Advanced Healthcare Materials (2019)

In article number 1900157 by Qianjun He and co-workers, a two-dimensional magnesium boride nanosheet (MBN) is developed as a new type of acid-responsive hydrogen-releasing prodrug to realize combined hydrogenochemotherapy of gastric cancer by oral uptake of an MBN@PVP pill, reducing toxic side effects and enhancing anticancer outcomes of chemotherapy.
Leveraging Digital Health and Machine Learning Toward Reducing Suicide—From Panacea to Practical Tool
Authors: John Torous, Rheeda Walker
Journal: JAMA Psychiatry (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
Abstract 14519: Unique Cardiac Phenotype in ALPK3-Related Disease: Progression From Dilated Cardiomyopathy to Hypertrophic Cardiomyopathy
Authors: Johanna C Herkert, Judith M Verhagen, Dean G Phelan, Paul A James, Natasha J Brown, Chloe Stutterd, Ivan Macciocca, Anu Aggarwal, Bert Timmer, Marion L Bulthuis, Yolande van Bever, Amy E Roberts, Christine E Seidman, Neal K Lakdawala, Michael A Burke, Mary Ella Pierpont, Irene M van Langen, Jan D Jongbloed, Paul J Lockhart, David J Amor, Ingrid M van de Laar
Journal: Circulation (2018)

Introduction: Biallelic truncating variants in ALPK3 have recently been described to cause pediatric cardiomyopathy (CMP). Functional studies have found disorganized intercalated discs and sarcomer...
Association of Screen Time and Depression in Adolescence
Authors: Elroy Boers, Mohammad H. Afzali, Nicola Newton, Patricia Conrod
Journal: JAMA Pediatrics (2019)

Increases in screen time have been found to be associated with increases in depressive symptoms. However, longitudinal studies are lacking.To repeatedly measure the association between screen time and depression to test 3 explanatory hypotheses: displacement, upward social comparison, and reinforcing spirals.This secondary analysis used data from a randomized clinical trial assessing the 4-year efficacy of a personality-targeted drug and alcohol prevention intervention. This study assessed screen time and depression throughout 4 years, using an annual survey in a sample of adolescents who entered the seventh grade in 31 schools in the Greater Montreal area. Data were collected from September 2012 to September 2018. Analysis began and ended in December 2018.Independent variables were social media, television, video gaming, and computer use. Symptoms of depression was the outcome, measured using the Brief Symptoms Inventory. Exercise and self-esteem were assessed to test displacement and upward social comparison hypothesis.A total of 3826 adolescents (1798 girls [47%]; mean [SD] age, 12.7 [0.5] years) were included. In general, depression symptoms increased yearly (year 1 mean [SD], 4.29 [5.10] points; year 4 mean [SD], 5.45 [5.93] points). Multilevel models, which included random intercepts at the school and individual level estimated between-person and within-person associations between screen time and depression. Significant between-person associations showed that for every increased hour spent using social media, adolescents showed a 0.64-unit increase in depressive symptoms (95% CI, 0.32-0.51). Similar between-level associations were reported for computer use (0.69; 95% CI, 0.47-0.91). Significant within-person associations revealed that a further 1-hour increase in social media use in a given year was associated with a further 0.41-unit increase in depressive symptoms in that same year. A similar within-person association was found for television (0.18; 95% CI, 0.09-0.27). Significant between-person and within-person associations between screen time and exercise and self-esteem supported upward social comparison and not displacement hypothesis. Furthermore, a significant interaction between the between-person and within-person associations concerning social media and self-esteem supported reinforcing spirals hypothesis.Time-varying associations between social media, television, and depression were found, which appeared to be more explained by upward social comparison and reinforcing spirals hypotheses than by the displacement hypothesis. Both screen time modes should be taken into account when developing preventive measures and when advising parents.
Deciphering the molecular morphology of the human hair cycle: Wnt signalling during the telogen–anagen transformation
Authors: N.J. Hawkshaw, J.A. Hardman, M. Alam, F. Jimenez, R. Paus
Journal: British Journal of Dermatology (2019)

The signals that induce anagen (growth) in 'quiescent' human telogen hair follicles (HFs) are as yet unknown. Their identification promises better targeted therapeutic hair growth interventions.Recognizing the central role of Wnt signalling in hair biology, the aim was to delineate the differential expression of key agonists, antagonists and target genes of this pathway during the telogen-to-anagen transformation of human scalp HFs.This differential expression was studied by in situ hybridization in human telogen and early-anagen scalp HF sections.On anagen induction, gene expression of the Wnt ligands WNT3, WNT4 and WNT10B, the Wnt ligand secretion regulator WLS, and the Wnt target genes AXIN2 and LEF1, is significantly increased within the secondary hair germ and the dermal papilla. Conversely, expression of the secreted Wnt inhibitor SFRP1 (secreted frizzled-related protein 1) is reduced. Human epithelial HF stem cells upregulate WNT4 and WNT10A expression, suggesting that these Wnt agonists are important for stem cell activation.We provide the first evidence that key changes in Wnt signalling that drive murine anagen induction also occur in human scalp HFs, yet with notable differences. This provides a rational basis for Wnt-targeting therapeutic interventions to manipulate human hair growth disorders. What's already known about this topic? Upregulation of Wnt agonists and downregulation of Wnt antagonists in the secondary hair germ and/or dermal papilla drives hair growth (anagen) induction in mice. Autocrine Wnt signalling in murine epithelial hair follicle stem cells is required to maintain their stem cell function. Reduction of Wnt ligands or increased expression of Wnt antagonists induces dysregulation of the murine hair follicle cycle and causes alopecia. What does this study add? This study demonstrates for the first time that key Wnt pathway regulatory agonists, antagonists and target genes, are expressed in the human telogen-to-early-anagen transformation. On human anagen induction the Wnt ligands WNT3, WNT4 and WNT10B are increased in the regenerating epithelium, whereas the Wnt antagonist, SFRP1 (secreted frizzled-related protein 1), is reduced. Human anagen induction has fundamental differences in the expression of Wnt ligands compared with the murine system. What is the translational message? Regulation of these Wnt ligands permits targeted therapeutic interventions in human hair growth disorders and informs development of new drugs that promote or suppress anagen induction.
Timing of implant-removal in late acute periprosthetic joint infection: A multicenter observational study
Authors: Marjan Wouthuyzen-Bakker, Marine Sebillotte, Jose Lomas, Benjamin Kendrick, Eva Benavent Palomares, Oscar Murillo, Javad Parvizi, Noam Shohat, Javier Cobo Reinoso, Rosa Escudero Sánchez, Marta Fernandez-Sampedro, Eric Senneville, Kaisa Huotari, José Maria Barbero Allende, Antonio Blanco García, Jaime Lora-Tamayo, Matteo Carlo Ferrari, Danguole Vaznaisiene, Erlangga Yusuf, Craig Aboltins, Rihard Trebse, Mauro José Salles, Natividad Benito, Andrea Vila, Maria Dolores Del Toro, Tobias Siegfried Kramer, Sabine Petersdorf, Vicens Diaz-Brito, Zeliha Kocak Tufan, Marisa Sanchez, Cédric Arvieux, Alex Soriano
Journal: Journal of Infection (2019)